Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

  • Cytokine release syndrome

    Journal for ImmunoTherapy of Cancer Open Access 15 June 2018

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224ra25.

    Article  Google Scholar 

  2. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509–1518.

    Article  CAS  Google Scholar 

  3. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012; 18: 1859–1866.

    Article  Google Scholar 

  4. O'Donnell P, Raj K, Pagliuca A . High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant 2015; 21: 197–198.

    Article  Google Scholar 

  5. Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP et al. Severe cytokine release syndrome following T-cell replete peripheral blood haploidentical donor transplant is associated with poor survival and anti-IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant 2016; 22: 1851–1860.

    Article  CAS  Google Scholar 

  6. Holtzman NG, Badros A, Kocoglu M, Landau M, Minas NM, Nishioka J et al. Tocilizumab is effective therapy for cytokine release syndrome after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Biol Blood Marrow Transplant 2016; 22: S324.

    Article  Google Scholar 

  7. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1835–1844.

    Article  Google Scholar 

  8. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  Google Scholar 

  9. Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20: 890–895.

    Article  Google Scholar 

  10. Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Halwani AS et al. Safety and efficacy of allogeneic hematopoetic stem cell transplant (HSCT) after treatment with programmed cell death 1 (PD-1) inhibitors. Blood 2015; 126: 2018–2018.

    Google Scholar 

Download references

Acknowledgements

This research was supported in part by NIH/NCI Cancer Center Support Grant P30 CA008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M A Perales.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cho, C., Perales, M. Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab. Bone Marrow Transplant 51, 1620–1621 (2016). https://doi.org/10.1038/bmt.2016.229

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.229

This article is cited by

Search

Quick links